

RNAi for Therapeutic-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/R3E2AEEBAECEN.html>

Date: February 2018

Pages: 146

Price: US\$ 3,480.00 (Single User License)

ID: R3E2AEEBAECEN

Abstracts

Report Summary

RNAi for Therapeutic-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on RNAi for Therapeutic industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of RNAi for Therapeutic 2013-2017, and development forecast 2018-2023

Main market players of RNAi for Therapeutic in United States, with company and product introduction, position in the RNAi for Therapeutic market

Market status and development trend of RNAi for Therapeutic by types and applications

Cost and profit status of RNAi for Therapeutic, and marketing status

Market growth drivers and challenges

The report segments the United States RNAi for Therapeutic market as:

United States RNAi for Therapeutic Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest

The West

The South

Southwest

United States RNAi for Therapeutic Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

siRNA
miRNA
shRNA

United States RNAi for Therapeutic Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Cancer
Cardiovascular
HBV
Other

United States RNAi for Therapeutic Market: Players Segment Analysis (Company and Product introduction, RNAi for Therapeutic Sales Volume, Revenue, Price and Gross Margin):

Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead Research
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
Miragen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Arcturus Therapeutics
Ariz Biopharma
Celsion Corporation

Asclepis Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF RNAI FOR THERAPEUTIC

- 1.1 Definition of RNAi for Therapeutic in This Report
- 1.2 Commercial Types of RNAi for Therapeutic
 - 1.2.1 siRNA
 - 1.2.2 miRNA
 - 1.2.3 shRNA
- 1.3 Downstream Application of RNAi for Therapeutic
 - 1.3.1 Cancer
 - 1.3.2 Cardiovascular
 - 1.3.3 HBV
 - 1.3.4 Other
- 1.4 Development History of RNAi for Therapeutic
- 1.5 Market Status and Trend of RNAi for Therapeutic 2013-2023
 - 1.5.1 United States RNAi for Therapeutic Market Status and Trend 2013-2023
 - 1.5.2 Regional RNAi for Therapeutic Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of RNAi for Therapeutic in United States 2013-2017
- 2.2 Consumption Market of RNAi for Therapeutic in United States by Regions
 - 2.2.1 Consumption Volume of RNAi for Therapeutic in United States by Regions
 - 2.2.2 Revenue of RNAi for Therapeutic in United States by Regions
- 2.3 Market Analysis of RNAi for Therapeutic in United States by Regions
 - 2.3.1 Market Analysis of RNAi for Therapeutic in New England 2013-2017
 - 2.3.2 Market Analysis of RNAi for Therapeutic in The Middle Atlantic 2013-2017
 - 2.3.3 Market Analysis of RNAi for Therapeutic in The Midwest 2013-2017
 - 2.3.4 Market Analysis of RNAi for Therapeutic in The West 2013-2017
 - 2.3.5 Market Analysis of RNAi for Therapeutic in The South 2013-2017
 - 2.3.6 Market Analysis of RNAi for Therapeutic in Southwest 2013-2017
- 2.4 Market Development Forecast of RNAi for Therapeutic in United States 2018-2023
 - 2.4.1 Market Development Forecast of RNAi for Therapeutic in United States 2018-2023
 - 2.4.2 Market Development Forecast of RNAi for Therapeutic by Regions 2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole United States Market Status by Types
 - 3.1.1 Consumption Volume of RNAi for Therapeutic in United States by Types
 - 3.1.2 Revenue of RNAi for Therapeutic in United States by Types
- 3.2 United States Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in New England
 - 3.2.2 Market Status by Types in The Middle Atlantic
 - 3.2.3 Market Status by Types in The Midwest
 - 3.2.4 Market Status by Types in The West
 - 3.2.5 Market Status by Types in The South
 - 3.2.6 Market Status by Types in Southwest
- 3.3 Market Forecast of RNAi for Therapeutic in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of RNAi for Therapeutic in United States by Downstream Industry
- 4.2 Demand Volume of RNAi for Therapeutic by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of RNAi for Therapeutic by Downstream Industry in New England
 - 4.2.2 Demand Volume of RNAi for Therapeutic by Downstream Industry in The Middle Atlantic
 - 4.2.3 Demand Volume of RNAi for Therapeutic by Downstream Industry in The Midwest
 - 4.2.4 Demand Volume of RNAi for Therapeutic by Downstream Industry in The West
 - 4.2.5 Demand Volume of RNAi for Therapeutic by Downstream Industry in The South
 - 4.2.6 Demand Volume of RNAi for Therapeutic by Downstream Industry in Southwest
- 4.3 Market Forecast of RNAi for Therapeutic in United States by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF RNAI FOR THERAPEUTIC

- 5.1 United States Economy Situation and Trend Overview
- 5.2 RNAi for Therapeutic Downstream Industry Situation and Trend Overview

CHAPTER 6 RNAI FOR THERAPEUTIC MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

- 6.1 Sales Volume of RNAi for Therapeutic in United States by Major Players
- 6.2 Revenue of RNAi for Therapeutic in United States by Major Players

6.3 Basic Information of RNAi for Therapeutic by Major Players

6.3.1 Headquarters Location and Established Time of RNAi for Therapeutic Major Players

6.3.2 Employees and Revenue Level of RNAi for Therapeutic Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 RNAI FOR THERAPEUTIC MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Alnylam Pharmaceuticals

7.1.1 Company profile

7.1.2 Representative RNAi for Therapeutic Product

7.1.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals

7.2 Arbutus Biopharma (Tekmira)

7.2.1 Company profile

7.2.2 Representative RNAi for Therapeutic Product

7.2.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arbutus Biopharma (Tekmira)

7.3 Arrowhead Research

7.3.1 Company profile

7.3.2 Representative RNAi for Therapeutic Product

7.3.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arrowhead Research

7.4 Dicerna Pharmaceuticals

7.4.1 Company profile

7.4.2 Representative RNAi for Therapeutic Product

7.4.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Dicerna Pharmaceuticals

7.5 Mirna Therapeutics

7.5.1 Company profile

7.5.2 Representative RNAi for Therapeutic Product

7.5.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Mirna Therapeutics

7.6 Quark Pharmaceuticals

7.6.1 Company profile

- 7.6.2 Representative RNAi for Therapeutic Product
- 7.6.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Quark Pharmaceuticals
- 7.7 RXi Pharmaceuticals
 - 7.7.1 Company profile
 - 7.7.2 Representative RNAi for Therapeutic Product
 - 7.7.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of RXi Pharmaceuticals
- 7.8 Silence Therapeutics
 - 7.8.1 Company profile
 - 7.8.2 Representative RNAi for Therapeutic Product
 - 7.8.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Silence Therapeutics
- 7.9 Benitec Biopharma
 - 7.9.1 Company profile
 - 7.9.2 Representative RNAi for Therapeutic Product
 - 7.9.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Benitec Biopharma
- 7.10 Miragen Therapeutics
 - 7.10.1 Company profile
 - 7.10.2 Representative RNAi for Therapeutic Product
 - 7.10.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Miragen Therapeutics
- 7.11 Sylentis
 - 7.11.1 Company profile
 - 7.11.2 Representative RNAi for Therapeutic Product
 - 7.11.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Sylentis
- 7.12 Gradalis
 - 7.12.1 Company profile
 - 7.12.2 Representative RNAi for Therapeutic Product
 - 7.12.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Gradalis
- 7.13 Sirnaomics
 - 7.13.1 Company profile
 - 7.13.2 Representative RNAi for Therapeutic Product
 - 7.13.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Sirnaomics
- 7.14 Silenseed
 - 7.14.1 Company profile
 - 7.14.2 Representative RNAi for Therapeutic Product
 - 7.14.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Silenseed

7.15 Arcturus Therapeutics

7.15.1 Company profile

7.15.2 Representative RNAi for Therapeutic Product

7.15.3 RNAi for Therapeutic Sales, Revenue, Price and Gross Margin of Arcturus Therapeutics

7.16 Ariz Biopharma

7.17 Celsion Corporation

7.18 Ascleptis Pharmaceuticals

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF RNAI FOR THERAPEUTIC

8.1 Industry Chain of RNAi for Therapeutic

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF RNAI FOR THERAPEUTIC

9.1 Cost Structure Analysis of RNAi for Therapeutic

9.2 Raw Materials Cost Analysis of RNAi for Therapeutic

9.3 Labor Cost Analysis of RNAi for Therapeutic

9.4 Manufacturing Expenses Analysis of RNAi for Therapeutic

CHAPTER 10 MARKETING STATUS ANALYSIS OF RNAI FOR THERAPEUTIC

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: RNAi for Therapeutic-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/R3E2AEEBAECEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R3E2AEEBAECEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970